Connecting Omics Signatures and Revealing Biological Mechanisms with ILINCS

Overview

Journal Nat Commun

Specialty Biology

Date 2022 Aug 9

PMID 35945222

Authors

Marcin Pilarczyk

Mehdi Fazel-Najafabadi

Michal Kouril

Behrouz Shamsaei

Juozas Vasiliauskas

Wen Niu

Naim Mahi

Lixia Zhang

Nicholas A Clark

Yan Ren

Shana White

Rashid Karim

Huan Xu

Jacek Biesiada

Mark F Bennett

Sarah E Davidson

John F Reichard

Kurt Roberts

Vasileios Stathias

Amar Koleti

Dusica Vidovic

Daniel J B Clarke

Stephan C Schurer

Avi Maayan

Jarek Meller

Mario Medvedovic

Affiliations

Soon will be listed here.

Abstract

There are only a few platforms that integrate multiple omics data types, bioinformatics tools, and interfaces for integrative analyses and visualization that do not require programming skills. Here we present iLINCS ( http://ilincs.org ), an integrative web-based platform for analysis of omics data and signatures of cellular perturbations. The platform facilitates mining and re-analysis of the large collection of omics datasets (>34,000), pre-computed signatures (>200,000), and their connections, as well as the analysis of user-submitted omics signatures of diseases and cellular perturbations. iLINCS analysis workflows integrate vast omics data resources and a range of analytics and interactive visualization tools into a comprehensive platform for analysis of omics signatures. iLINCS user-friendly interfaces enable execution of sophisticated analyses of omics signatures, mechanism of action analysis, and signature-driven drug repositioning. We illustrate the utility of iLINCS with three use cases involving analysis of cancer proteogenomic signatures, COVID 19 transcriptomic signatures and mTOR signaling.

Citing Articles

Identification and multi-omics analysis of essential coding and long non-coding genes in colorectal cancer.

Li Y, Meng Z, Fan C, Rong H, Xi Y, Liao Q Biochem Biophys Rep. 2025; 41:101938.

PMID: 40034256 PMC: 11874739. DOI: 10.1016/j.bbrep.2025.101938.

Adaptive Proteomic Changes in Protein Metabolism and Mitochondrial Alterations Associated with Resistance to Trastuzumab and Pertuzumab Therapy in HER2-Positive Breast Cancer.

Madoz-Gurpide J, Serrano-Lopez J, Sanz-Alvarez M, Morales-Gallego M, Rodriguez-Pinilla S, Rovira A Int J Mol Sci. 2025; 26(4).

PMID: 40004024 PMC: 11855744. DOI: 10.3390/ijms26041559.

Reversal gene expression assessment for drug repurposing, a case study of glioblastoma.

Sun S, Shyr Z, McDaniel K, Fang Y, Tao D, Chen C J Transl Med. 2025; 23(1):25.

PMID: 39773231 PMC: 11706105. DOI: 10.1186/s12967-024-06046-1.

Identification of Transcriptional Regulators of Immune Evasion Across Cancers: An Alternative Immunotherapeutic Strategy for Cholangiocarcinoma.

Venkatraman S, Balasubramanian B, Kongpracha P, Yangngam S, Chuangchot N, Khanaruksombat S Cancers (Basel). 2025; 16(24.

PMID: 39766097 PMC: 11674672. DOI: 10.3390/cancers16244197.

OSI-027 as a Potential Drug Candidate Targeting Upregulated Hub Protein TAF1 in Potential Mechanism of Sinonasal Squamous Cell Carcinoma: Insights from Proteomics and Molecular Docking.

Panthong W, Pientong C, Nukpook T, Heawchaiyaphum C, Aromseree S, Ekalaksananan T Biology (Basel). 2025; 13(12.

PMID: 39765756 PMC: 11673211. DOI: 10.3390/biology13121089.

References

Spilman P, Podlutskaya N, Hart M, Debnath J, Gorostiza O, Bredesen D . Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS One. 2010; 5(4):e9979. PMC: 2848616. DOI: 10.1371/journal.pone.0009979. View

Koleti A, Terryn R, Stathias V, Chung C, Cooper D, Turner J . Data Portal for the Library of Integrated Network-based Cellular Signatures (LINCS) program: integrated access to diverse large-scale cellular perturbation response data. Nucleic Acids Res. 2017; 46(D1):D558-D566. PMC: 5753343. DOI: 10.1093/nar/gkx1063. View

Anda-Jauregui G, Hernandez-Lemus E . Computational Oncology in the Multi-Omics Era: State of the Art. Front Oncol. 2020; 10:423. PMC: 7154096. DOI: 10.3389/fonc.2020.00423. View

Jiang Y, Shi X, Zhao Q, Krauthammer M, Gould Rothberg B, Ma S . Integrated analysis of multidimensional omics data on cutaneous melanoma prognosis. Genomics. 2016; 107(6):223-30. PMC: 4893887. DOI: 10.1016/j.ygeno.2016.04.005. View

Al Mahi N, Zhang E, Sherman S, Yu J, Medvedovic M . Connectivity Map Analysis of a Single-Cell RNA-Sequencing -Derived Transcriptional Signature of mTOR Signaling. Int J Mol Sci. 2021; 22(9). PMC: 8122562. DOI: 10.3390/ijms22094371. View

Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov J, Tamayo P . The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2016; 1(6):417-425. PMC: 4707969. DOI: 10.1016/j.cels.2015.12.004. View

Barrett T, Troup D, Wilhite S, Ledoux P, Rudnev D, Evangelista C . NCBI GEO: archive for high-throughput functional genomic data. Nucleic Acids Res. 2008; 37(Database issue):D885-90. PMC: 2686538. DOI: 10.1093/nar/gkn764. View

Duan Q, Reid S, Clark N, Wang Z, Fernandez N, Rouillard A . L1000CDS: LINCS L1000 characteristic direction signatures search engine. NPJ Syst Biol Appl. 2017; 2. PMC: 5389891. DOI: 10.1038/npjsba.2016.15. View

Kuleshov M, Jones M, Rouillard A, Fernandez N, Duan Q, Wang Z . Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016; 44(W1):W90-7. PMC: 4987924. DOI: 10.1093/nar/gkw377. View

10.

Kim S, Thiessen P, Bolton E, Chen J, Fu G, Gindulyte A . PubChem Substance and Compound databases. Nucleic Acids Res. 2015; 44(D1):D1202-13. PMC: 4702940. DOI: 10.1093/nar/gkv951. View

11.

Clarke D, Kuleshov M, Schilder B, Torre D, Duffy M, Keenan A . eXpression2Kinases (X2K) Web: linking expression signatures to upstream cell signaling networks. Nucleic Acids Res. 2018; 46(W1):W171-W179. PMC: 6030863. DOI: 10.1093/nar/gky458. View

12.

Yu K, Shi C, Toral-Barza L, Lucas J, Shor B, Kim J . Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res. 2010; 70(2):621-31. DOI: 10.1158/0008-5472.CAN-09-2340. View

13.

Tarca A, Bhatti G, Romero R . A comparison of gene set analysis methods in terms of sensitivity, prioritization and specificity. PLoS One. 2013; 8(11):e79217. PMC: 3829842. DOI: 10.1371/journal.pone.0079217. View

14.

McMahon S, Monroe J . The role of early growth response gene 1 (egr-1) in regulation of the immune response. J Leukoc Biol. 1996; 60(2):159-66. DOI: 10.1002/jlb.60.2.159. View

15.

Tarca A, Draghici S, Khatri P, Hassan S, Mittal P, Kim J . A novel signaling pathway impact analysis. Bioinformatics. 2008; 25(1):75-82. PMC: 2732297. DOI: 10.1093/bioinformatics/btn577. View

16.

Stathias V, Turner J, Koleti A, Vidovic D, Cooper D, Fazel-Najafabadi M . LINCS Data Portal 2.0: next generation access point for perturbation-response signatures. Nucleic Acids Res. 2019; 48(D1):D431-D439. PMC: 7145650. DOI: 10.1093/nar/gkz1023. View

17.

Shavlakadze T, Zhu J, Wang S, Zhou W, Morin B, Egerman M . Short-term Low-Dose mTORC1 Inhibition in Aged Rats Counter-Regulates Age-Related Gene Changes and Blocks Age-Related Kidney Pathology. J Gerontol A Biol Sci Med Sci. 2018; 73(7):845-852. PMC: 6001891. DOI: 10.1093/gerona/glx249. View

18.

Stromback L, Jakoniene V, Tan H, Lambrix P . Representing, storing and accessing molecular interaction data: a review of models and tools. Brief Bioinform. 2006; 7(4):331-8. DOI: 10.1093/bib/bbl039. View

19.

Safran M, Dalah I, Alexander J, Rosen N, Iny Stein T, Shmoish M . GeneCards Version 3: the human gene integrator. Database (Oxford). 2010; 2010:baq020. PMC: 2938269. DOI: 10.1093/database/baq020. View

20.

Weisberg E, Parent A, Yang P, Sattler M, Liu Q, Liu Q . Repurposing of Kinase Inhibitors for Treatment of COVID-19. Pharm Res. 2020; 37(9):167. PMC: 7417114. DOI: 10.1007/s11095-020-02851-7. View